title: The importance of patient-centred care to overcome barriers in the management of actinic keratosis.
abstract: Visible actinic keratosis (AK) lesions and subclinical (non-visible) sun damage in the field of cancerization are associated with risk of both non-melanoma skin cancer, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), and, more rarely, melanoma. As the incidences of AK and skin cancer are increasing, effective prevention and treatment of AK is essential to minimize disease burden and improve patient quality of life. Currently, AK lesions are often left untreated and field therapies are underused. Patient-centred care, with a focus on the patient-physician relationship, has proven cost-effective, and improved clinical outcomes and patient satisfaction in a number of therapy areas. Strategies for applying patient-centred care to AK are warranted. Existing barriers to the effective treatment of AK were identified and patient-centric strategies to overcome each barrier were discussed. Barriers to effective AK treatment include poor disease awareness (for both patient and physician), concerns associated with the cosmetic effects of treatment, treatment-related side effects, cost perceptions for lesion-directed vs field-directed therapies, and inadequate adherence, particularly with long treatment duration. Overcoming these barriers will involve patient and physician education that promotes: disease prevention and awareness; the importance of self-examination; an understanding of treatment options; and the importance of adherence to treatment. To maximize its effectiveness, education should be delivered within a patient-centric framework, where the relationship between patient and physician is built on effective communication, empathy and a feeling of partnership. Patient-centric care, including patient education, is key to overcoming the barriers associated with effective AK treatment.
authors.affiliation: Department of Cutaneous Medicine & Surgery, The Royal London Hospital & QMUL, Bart's Health NHS Trust, Whitechapel, London, UK.
authors.forename: R
authors.initials: R
authors.lastname: Cerio
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D002280:Basal Cell Carcinoma / Q000517:prevention & control*; D002294:Carcinoma, Squamous Cell / Q000517:prevention & control*; D006801:Humans; D055623:Keratosis, Actinic / Q000628:therapy*; D010353:Patient Education as Topic; D018802:Patient-Centered Care; D010817:Physician-Patient Relations; D012878:Skin Neoplasms / Q000517:prevention & control*
chemical_list: D000970:Antineoplastic Agents